4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six years Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditionsFindings reinforce safety profile and support expanded adoption of ReWalk for spinal cord injury mobility Lifeward CEO Mark Grant addressed the 53rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovativ

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company's previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (NASDAQ:ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed's clinical-stage Protein Oral Delivery (POD™) technology, adding exposure to a large, long-term biotech market opportunity

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities,

Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which the Company satisfied

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-

Clinic days offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years, with the goal of accelerating personal exoskeleton adoption Streamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced a joint effort with Shirley Ryan AbilityLab, a global leader in physical medicine and rehabilitation. This collaboration will establish dedicated clinic days launching in

4 - Lifeward Ltd. (0001607962) (Issuer)

3 - Lifeward Ltd. (0001607962) (Issuer)

3 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

3 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

3 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

4 - Lifeward Ltd. (0001607962) (Issuer)

Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

SD - Lifeward Ltd. (0001607962) (Filer)

S-8 - Lifeward Ltd. (0001607962) (Filer)

10-Q - Lifeward Ltd. (0001607962) (Filer)

8-K - Lifeward Ltd. (0001607962) (Filer)

NT 10-Q - Lifeward Ltd. (0001607962) (Filer)

8-K - Lifeward Ltd. (0001607962) (Filer)

SCHEDULE 13D - Lifeward Ltd. (0001607962) (Subject)

EFFECT - Lifeward Ltd. (0001607962) (Filer)

DEL AM - Lifeward Ltd. (0001607962) (Filer)

S-3 - Lifeward Ltd. (0001607962) (Filer)

Veteran physician, medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience, mobility technologies, and metabolic disease Promotion reflects Lifeward's continued investment in clinical innovation, evidence generation, and patient outcomes across its expanding med-tech rehabilitation and biomed technology portfolio HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the Board of Directors has approved the appointment of Robert J. Marshall Jr. as a new director effective November 2, 2024. As part of his duties as a director, Mr. Marshall will serve as Chairman of the Audit Committee. Mr. Marshall has had a long and accomplished finance career in the medical device industry. Currently, Mr. Marshall serves as the Chief Financial Officer and Treasurer of Lantheus Holdings, Inc., a publicly traded radiopharmaceut

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Dr. Keith E. Tansey, MD, PhD, will be joining its Medical Affairs team as a consultant in the role of Director, Clinical Research. Dr. Tansey's responsibilities will include the development and stewardship of Lifeward's clinical research program, the advancement of key opinion leader opportunities, and iden

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that Jeff Dykan, current Chairman of the Lifeward Board of Directors, will retire from his role and will not stand for reelection effective at the 2024 Annual Meeting of Shareholders. Joseph Turk, who has served on Lifeward's Board since 2022, has been appointed as the incoming Chairman and will assume the role f

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™) (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market lead delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, announced that the Board has approved the appointment of Mike Swinford to the Board of Directors, effective April 18, 2024. Mr. Swinford has been Chief Executive Officer of Numotion since July 2014, where he has grown the company to become the largest provider of mobility and independence solutions in the United States - serving

Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNE

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026. Following the news release, Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll fre

Positions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that its shareholders approved the issuances of ordinary shares of the Company in connection with closing of the Co

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 3

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561Inte

Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended June 30, 2025. Recent Highlights and Accomplishments for Lifeward Achieve

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Vice President of Finance, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-05

U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and A

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a  global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025. Larry Jasinski, Chief Executive Officer, and Mike Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561International (